New antibody treatment trial targets chronic back pain disease
NCT ID NCT06526377
Summary
This study is testing whether adding weekly Natrunix injections to standard care helps people with active axial spondyloarthritis, a type of inflammatory spinal arthritis. The trial will include 60 participants who are HLA-B27 positive and have active disease symptoms. Participants will receive either Natrunix or a placebo injection along with their current treatment for 12 weeks to see if it improves their symptoms and function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.